These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24756215)

  • 1. Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan.
    Chen JR; Hsieh TY; Chen HY; Yeh KY; Chen KS; ChangChien YC; Pintye M; Chang LC; Hwang CC; Chien HP; Hsu YC
    Virchows Arch; 2014 Jun; 464(6):689-99. PubMed ID: 24756215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry.
    Tabarestani S; Ghaderian SM; Rezvani H
    Asian Pac J Cancer Prev; 2015; 16(17):7997-8002. PubMed ID: 26625832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study.
    Moelans CB; Monsuur HN; de Pinth JH; Radersma RD; de Weger RA; van Diest PJ
    Anal Cell Pathol (Amst); 2010; 33(1):13-8. PubMed ID: 20966540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation.
    Lin CH; Liu JM; Lu YS; Lan C; Lee WC; Kuo KT; Wang CC; Chang DY; Huang CS; Cheng AL
    J Clin Pathol; 2013 Feb; 66(2):140-5. PubMed ID: 23268322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study.
    Ooi A; Inokuchi M; Harada S; Inazawa J; Tajiri R; Kitamura SS; Ikeda H; Kawashima H; Dobashi Y
    J Pathol; 2012 May; 227(1):8-16. PubMed ID: 22170254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
    Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
    PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
    Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
    Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
    Holst F; Stahl PR; Ruiz C; Hellwinkel O; Jehan Z; Wendland M; Lebeau A; Terracciano L; Al-Kuraya K; Jänicke F; Sauter G; Simon R
    Nat Genet; 2007 May; 39(5):655-60. PubMed ID: 17417639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
    Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
    Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
    Seol H; Lee HJ; Choi Y; Lee HE; Kim YJ; Kim JH; Kang E; Kim SW; Park SY
    Mod Pathol; 2012 Jul; 25(7):938-48. PubMed ID: 22388760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
    Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
    Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.